A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America

Completed

Conditions: Respiratory Syncytial Virus Infection

Registration Number: NCT01297504

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Brief Summary: The study was designed to gather information regarding the use of palivizumab for the prophylaxis for respiratory syncytial virus (RSV) infection in high-risk infants in selected countries within Latin America.

Detailed Description: RSV causes significant disease. There is a paucity of data from developing countries even though existing data clearly indicate that RSV accounts for a high proportion of acute respiratory illnesses (ARIs) in children.

This is a multi-center study in a cohort of infants at risk for RSV infection in Latin America who have received palivizumab in the usual manner in accordance with the terms of marketing authorization with regard to dose, population and indication. Enrolled participants were followed for one year after their first dose of palivizumab. Epidemiological and clinical data as well as information about compliance, hospitalizations and safety was collected.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 464

Inclusion Criteria

Children with a history of bronchopulmonary dysplasia, infants with a history of prematurity (less than or equal to 35 weeks gestational age), or children with hemodynamically significant congenital heart disease who received the first dose of palivizumab within the 2 weeks prior to the signature of the Informed Consent Form.
Parent or legal guardian of child provides written Informed Consent

Exclusion Criteria

Children excluded from receiving palivizumab as per local guidelines

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Characterization of Participants With Risk Factors for Respiratory Syncytial Virus (RSV) Infection	Baseline	Study participants were characterized at Baseline by history of bronchopulmonary dysplasia, history of prematurity (less than or equal to 35 weeks gestational age), children with hemodynamically significant congenital heart disease (CHD), the presence of cohabitants less than 6 years old, possible exposure to indoor tobacco smoke, day care attendance, asthmatic or atopic mother, smoking during pregnancy, breastfeeding, prenatal assistance (4 or more visits during pregnancy), neonatal hospitalization care, history of neonatal assisted ventilation, and mother education level (completed primary school).
Distribution of Comorbidities in Study Participants	Baseline	The percentage of participants with each and combinations of the three comorbidities for which palivizumab is indicated.

Secondary Outcome Measures

Name	Time	Method
Characterization of Hospitalization Episodes Due to Lower Respiratory Tract Infection and RSV	12 months
Risk Factors for Hospitalization	Baseline and 12 months	Variables that could act as risk factors for hospitalization for lower respiratory tract infection were tested in univariate and multivariate Poisson regression models. Baseline characteristics, such as age, gender, birth weight and comorbidities were included as covariates in the Poisson regression model. Variables for multivariate analysis were added applying forward selection. Gestational age and birth weight were included as continuous variables, considering that the higher they were the better they could act as a protection factor for hospitalization due to respiratory infection.
Compliance to Prescribed Palivizumab	12 months	Compliance to prescribed palivizumab was calculated based on the number of doses received versus the expected number of doses for each participant. The expected number of doses for each participant was estimated based on seasonality and current prescription guidelines for each country.
Mean Number of Doses of Palivizumab Administered	12 months
Number of Participants With Hospitalizations for Lower Respiratory Tract Infection and RSV	12 months	The number of participants with hospitalizations due to lower respiratory tract infection (LRTI) and hospitalizations due to lower respiratory tract infection caused by RSV.

Trial Locations

Locations (24): Site Reference ID/Investigator# 52723
🇨🇴
Bogota, Colombia
Site Reference ID/Investigator# 52084
🇲🇽
Mexico City, DF, Mexico
Site Reference ID/Investigator# 52726
🇨🇴
Barranquilla, Colombia
Site Reference ID/Investigator# 52729
🇨🇴
Bogota, Colombia
Site Reference ID/Investigator# 52735
🇨🇴
Cali, Colombia
Site Reference ID/Investigator# 52731
🇨🇴
Medellin, Colombia
Site Reference ID/Investigator# 52083
🇲🇽
Nuevo Leon, Monterrey, Mexico
Site Reference ID/Investigator# 52184
🇦🇷
Buenos Aires, Argentina
Site Reference ID/Investigator# 52703
🇪🇨
Quito, Ecuador
Site Reference ID/Investigator# 52704
🇪🇨
Quito, Ecuador
Site Reference ID/Investigator# 52082
🇲🇽
Guanajuato, Leon, Mexico
Site Reference ID/Investigator# 52243
🇵🇪
Callao, Peru
Site Reference ID/Investigator# 52185
🇦🇷
Buenos Aires, Argentina
Site Reference ID/Investigator# 52182
🇦🇷
Buenos Aires, Argentina
Site Reference ID/Investigator# 54427
🇨🇱
Santiago, Chile
Site Reference ID/Investigator# 52183
🇦🇷
Buenos Aires, Argentina
Site Reference ID/Investigator# 54426
🇨🇱
Santiago, Chile
Site Reference ID/Investigator# 52732
🇨🇴
Armenia, Colombia
Site Reference ID/Investigator# 52722
🇨🇴
Barranquilla, Colombia
Site Reference ID/Investigator# 52725
🇨🇴
Bogota, Colombia
Site Reference ID/Investigator# 52727
🇨🇴
Bogota, Colombia
Site Reference ID/Investigator# 63882
🇨🇴
Bogota, Colombia
Site Reference ID/Investigator# 52242
🇵🇪
Lima, Peru
Site Reference ID/Investigator# 52246
🇺🇾
Salto, Uruguay